Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Authors Ajoy Kumar, Vibhuti Singh

Published Date July 2010 Volume 2010:6 Pages 665—669

DOI http://dx.doi.org/10.2147/VHRM.S5686

Published 30 July 2010

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Diffuse cerebral vasospasm after resection of schwannoma: a case report

Qi J,Zhang LW, Jia W, Zhang JT, Wu Z

Neuropsychiatric Disease and Treatment 2015, 11:317-320

Published Date: 5 February 2015

A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo

Huang Y, Yang T, Zhang W, Lu Y, Ye P, Yang G, Li B, Qi S, Liu Y, He X, Lee RJ, Xu C, Xiang G

International Journal of Nanomedicine 2014, 9:4581-4595

Published Date: 29 September 2014

The epidemiology of irritable bowel syndrome

Canavan C, West J, Card T

Clinical Epidemiology 2014, 6:71-80

Published Date: 4 February 2014

Incident prediabetes/diabetes and blood pressure in urban and rural communities in the Democratic Republic of Congo

Hightower JD, Hightower CM, Salazar Vázquez BY, Intaglietta M

Vascular Health and Risk Management 2011, 7:483-489

Published Date: 22 July 2011

Optimal management of familial hypercholesterolemia: treatment and management strategies

Mohammad Hassan Nemati, Behrooz Astaneh

Vascular Health and Risk Management 2010, 6:1079-1088

Published Date: 3 December 2010

Management of hypoactive sexual desire disorder in women: current and emerging therapies

Rossella E Nappi, Ellis Martini, Erica Terreno, et al

International Journal of Women's Health 2010, 2:167-175

Published Date: 1 July 2010

Atorvastatin in stroke: a review of SPARCL and subgroup analysis

Branko N Huisa, Andrew B Stemer, Justin A Zivin

Vascular Health and Risk Management 2010, 6:229-236

Published Date: 30 March 2010

Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy

Jeetesh V Patel, Inessa Tracey, Elizabeth A Hughes, et al

Vascular Health and Risk Management 2009, 5:801-810

Published Date: 21 September 2009

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes

Marc K Israel, Eva Istvan, Michelle A Baron

Vascular Health and Risk Management 2008, 4:1167-1178

Published Date: 2 September 2008

Risk factors for progression to blindness in high tension primary open angle glaucoma: Comparison of blind and nonblind subjects

Karanjit S Kooner, Mohannad AlBdoor, Byung J Cho, Beverley Adams-Huet

Clinical Ophthalmology 2008, 2:757-762

Published Date: 12 August 2008